Advanced search
Publication Cover
Expert Review of Endocrinology & Metabolism Volume 8, 2013 - Issue 3
Submit an article Journal homepage
81
Views
4
CrossRef citations to date
0
Altmetric
Drug Profile

Albiglutide: clinical overview of a long-acting GLP-1 receptor agonist in the treatment of Type 2 diabetes

Tracy Setji Duke University Medical Center, Durham, NC 27710, USA. [email protected]
&
Mark Feinglos Duke University Medical Center, Durham, NC 27710, USA
Pages 229-238 | Published online: 10 Jan 2014

References

  • Bennett WL, Odelola OA, Wilson LM et al. Evaluation of guideline recommendations on oral medications for Type 2 diabetes mellitus: a systematic review. Ann. Intern. Med. 156(1Pt 1), 27–36 (2012).
  • Inzucchi SE, Bergenstal RM, Buse JB et al.; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in Type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35(6), 1364–1379 (2012).
  • Holst JJ. The physiology of glucagon-like peptide 1. Physiol. Rev. 87(4), 1409–1439 (2007).
  • Kreyman B, Ghatei MA, Williams G, Bloom SR. Glucagon-like peptide-1 7–36: a physiological incretin in man. Lancet 2(8571), 1300–1301 (1987).
  • Vilsbøll T, Krarup T, Madsbad S, Holst JJ. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia 45(8), 1111–1119 (2002).
  • Rask E, Olsson T, Söderberg S et al. Insulin secretion and incretin hormones after oral glucose in nonobese subjects with impaired glucose tolerance. Metab. Clin. Exp. 53(5), 624–631 (2004).
  • Vilsbøll T, Krarup T, Sonne J et al. Incretin secretion in relation to meal size and bodyweight in healthy subjects and people with Type 1 and Type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 88(6), 2706–2713 (2003).
  • Toft-Nielsen MB, Damholt MB, Madsbad S et al. Determinants of the impaired secretion of glucagon-like peptide-1 in Type 2 diabetic patients. J. Clin. Endocrinol. Metab. 86(8), 3717–3723 (2001).
  • Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J. Clin. Endocrinol. Metab. 80(3), 952–957 (1995).
  • Vilsbøll T, Agersø H, Krarup T, Holst JJ. Similar elimination rates of glucagon-like peptide-1 in obese Type 2 diabetic patients and healthy subjects. J. Clin. Endocrinol. Metab. 88(1), 220–224 (2003).
  • Deacon CF, Knudsen LB, Madsen K, Wiberg FC, Jacobsen O, Holst JJ. Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1, which have extended metabolic stability and improved biological activity. Diabetologia 41(3), 271–278 (1998).
  • Edwards CM, Stanley SA, Davis R et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am. J. Physiol. Endocrinol. Metab. 281(1), E155–E161 (2001).
  • Byetta (exenatide), package insert. Amylin Pharmaceuticals, Inc., San Diego, CA, USA.
  • Feinglos MN, Saad MF, Pi-Sunyer FX, An B, Santiago O; Liraglutide Dose–Response Study Group. Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes. Diabet. Med. 22(8), 1016–1023 (2005).
  • Victoza® (liraglutide), package insert. Novo Nordisk, Inc., Princeton, NJ, USA.
  • Buse JB, Rosenstock J, Sesti G et al.; LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for Type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374(9683), 39–47 (2009).
  • Buse JB, Sesti G, Schmidt WE et al.; Liraglutide Effect Action in Diabetes-6 Study Group. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with Type 2 diabetes using oral agents. Diabetes Care 33(6), 1300–1303 (2010).
  • Buse JB, Montanya E, Sesti G et al. The incidence of antibody formation and the levels of antibodies are lower with liraglutide than exenatide in a head-to-head comparison. Diabetologia 53(Suppl. 1), S341 (2010).
  • Drucker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, Buse JB. Incretin-based therapies for the treatment of Type 2 diabetes: evaluation of the risks and benefits. Diabetes Care 33(2), 428–433 (2010).
  • Tracy MA, Ward KL, Firouzabadian L et al. Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheres in vivo and in vitro. Biomaterials 20(11), 1057–1062 (1999).
  • Bydureon® (exenatide extended-release), package insert. Amylin Pharmaceuticals, Inc., San Diego, CA, USA.
  • Drucker DJ, Buse JB, Taylor K et al.; DURATION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of Type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 372(9645), 1240–1250 (2008).
  • Blevins T, Pullman J, Malloy J et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice-daily in patients with Type 2 diabetes. J. Clin. Endocrinol. Metab. 96(5), 1301–1310 (2011).
  • Madsbad S, Kielgast U, Asmar M, Deacon CF, Torekov SS, Holst JJ. An overview of once-weekly glucagon-like peptide-1 receptor agonists – available efficacy and safety data and perspectives for the future. Diabetes Obes. Metab. 13(5), 394–407 (2011).
  • St Onge EL, Miller SA. Albiglutide: a new GLP-1 analog for the treatment of Type 2 diabetes. Expert Opin. Biol. Ther. 10(5), 801–806 (2010).
  • Dennis MS, Zhang M, Meng YG et al. Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J. Biol. Chem. 277(38), 35035–35043 (2002).
  • Bush MA, Matthews JE, De Boever EH et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects. Diabetes Obes. Metab. 11(5), 498–505 (2009).
  • Matthews JE, Stewart MW, De Boever EH et al.; Albiglutide Study Group. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with Type 2 diabetes. J. Clin. Endocrinol. Metab. 93(12), 4810–4817 (2008).
  • Rosenstock J, Reusch J, Bush M, Yang F, Stewart M; Albiglutide Study Group. Potential of albiglutide, a long-acting GLP-1 receptor agonist, in Type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care 32(10), 1880–1886 (2009).
  • Seino Y, Nakajima H, Miyahara H et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with Type 2 diabetes mellitus. Curr. Med. Res. Opin. 25(12), 3049–3057 (2009).
  • Seino Y, Rasmussen MF, Zdravkovic M, Kaku K. Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: a double-blind, randomized, controlled trial in Japanese patients with Type 2 diabetes. Diabetes Res. Clin. Pract. 81(2), 161–168 (2008).
  • Baggio LL, Huang Q, Brown TJ, Drucker DJ. A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 53(9), 2492–2500 (2004).
  • Kinzig KP, D’Alessio DA, Seeley RJ. The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness. J. Neurosci. 22(23), 10470–10476 (2002).
  • Grieve DJ, Cassidy RS, Green BD. Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control? Br. J. Pharmacol. 157(8), 1340–1351 (2009).
  • Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 54(1), 146–151 (2005).
  • Bose AK, Mocanu MM, Carr RD, Yellon DM. Glucagon like peptide-1 is protective against myocardial ischemia/reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model. Cardiovasc. Drugs Ther. 19(1), 9–11 (2005).
  • Zhao T, Parikh P, Bhashyam S et al. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J. Pharmacol. Exp. Ther. 317(3), 1106–1113 (2006).
  • Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 117(18), 2340–2350 (2008).
  • Noyan-Ashraf MH, Momen MA, Ban K et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 58(4), 975–983 (2009).
  • Bao W, Aravindhan K, Alsaid H et al. Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiency. PLoS ONE 6(8), e23570 (2011).
  • Timmers L, Henriques JP, de Kleijn DP et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J. Am. Coll. Cardiol. 53(6), 501–510 (2009).
  • Kristensen J, Mortensen UM, Schmidt M, Nielsen PH, Nielsen TT, Maeng M. Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model. BMC Cardiovasc. Disord. 9, 31 (2009).
  • Rosenstock J, Ahren B, Chow F et al. Once-weekly GLP-1 receptor agonist albiglutide vs. titrated prandial lispro added on to titrated basal insulin glargine in Type 2 diabetes (T2D) uncontrolled on glargine plus oral agents: similar glycemic control with weightloss and less hypoglycemia. Diabetes 61(Suppl. 1), A15 (2012).
  • Pratley RE, Barnett A, Feinglos M et al. Efficacy and safety of once-weekly (QW) albiglutide vs. once daily (QD) liraglutide in Type 2 diabetes (T2D) inadequately controlled on oral agents: harmony 7 trial. Diabetes 61(Suppl. 1), A240–A241 (2012).
  • Blonde L, Russell-Jones D. The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in Type 2 diabetes: an overview of the LEAD 1–5 studies. Diabetes Obes. Metab. 11(Suppl. 3), 26–34 (2009).
  • Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287(19), 2570–2581 (2002).
  • Monami M, Dicembrini I, Marchionni N, Rotella CM, Mannucci E. Effects of glucagon-like peptide-1 receptor agonists on bodyweight: a meta-analysis. Experimental Diabetes Res. doi:10.1155/2012/672658 (2012) (Epub ahead of print).
  • Williamson DF, Thompson TJ, Thun M, Flanders D, Pamuk E, Byers T. Intentional weightloss and mortality among overweight individuals with diabetes. Diabetes Care 23(10), 1499–1504 (2000).
  • Larsen J, Hylleberg B, Ng K, Damsbo P. Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in Type 2 diabetic patients who are poorly controlled on sulphonylurea treatment. Diabetes Care 24(8), 1416–1421 (2001).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.